Olympus Biotech Launches Opgenra, Formerly OP-1 (written by Lauren Uzdienski @ HealthPointCapital)
http://www.op1.com/
Olympus Biotech announced this week that the company launched their BMP-7 product, which they've named Opgenra, in Europe. Olympus acquired Opgenra, formerly OP-1, from Stryker late last year, paying $60 million for the OP-1 portfolio and the New Hampshire facility that manufactures it.
Opgenra is indicated for posterolateral lumbar spinal Fusion (PLF) in adult patients with spondylolisthesis where autograft has failed or is contraindicated. The product will be avail...
